borderline significantP = .069
Patients with ATTR medication had a numerically lower presence of ≥ moderate dyspnoea (NYHA class ≥ III), which was borderline significant (52.2% vs 65.0%, P = .069).
Patients with ATTR medication had a numerically lower presence of ≥ moderate dyspnoea (NYHA class ≥ III), which was borderline significant (52.2% vs 65.0%, P = .069).